Ian Hay1, Claire Aibel1, Abigail Blatchford1, Christopher B. Rohde1, Matthew Angel1
1Factor Bioscience Inc., Cambridge, MA
2024 ISSCR Annual Meeting
Chimeric antigen receptor T (CAR T) cell therapy’s profound clinical success in B-cell lymphoma and multiple myeloma cancer patients has not translated to solid tumors, which comprise 90% of cancer cases worldwide. A key barrier for CAR T therapy in solid tumors is their immunologically cold microenvironment which blocks T cells from functioning as cancer […]
Raven Dance Hinkel1, Elizabeth Belcher1, Christopher B. Rohde1, Matthew Angel1, Kyle M. Garland1
Mesenchymal stem cells (MSCs) are multipotent, relatively non-immunogenic, and can differentiate according to environmental cues, making them an ideal candidate for numerous allogeneic cell therapies. Moreover, MSCs have consistently demonstrated excellent safety profiles in clinical trials, but poor therapeutic responses have impeded their translational success. Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) engineered with stealthing […]
Elizabeth Belcher1, Raven Dance Hinkel1, Christopher B. Rohde1, Matthew Angel1, Kyle M. Garland1 1Factor Bioscience Inc., Cambridge, MA
Cellular therapies are an emerging field of medicine that involves the administration of cells as living agents to repair or replace damaged cells and tissues. While traditional cell therapies, such as autologous and donor-derived allogeneic therapies, hold great potential in combating intractable diseases, their clinical utility has been limited by several factors, including manufacturing complexities, […]
Ariadna Lubinus1, Joseph Pisano1, Christopher B. Rohde1, Matthew Angel1
Since the introduction of the mRNA COVID-19 vaccines, ionizable lipid-based mRNA delivery systems have gained attention for their potential applications in immunotherapy and tissue engineering. However, current chemical transfection reagents suffer from low transfection efficiency when transfecting mRNA into certain primary cells and stem cells. To address this, we designed a library of 4,200 lipids […]
Claire Aibel1, Abigail Blatchford1, Taeyun Kim1, Christopher B. Rohde1, Matthew Angel1
Cell therapies derived from knock-in human induced pluripotent stem cells (iPSCs) hold potential for increased scalability, broader accessibility, and superior production of genetically identical immune cells that express therapeutic transgenes. Such transgenes are often paired with synthetic promoters, which can drive high levels of protein expression but are often silenced during differentiation. To address this […]
Taeyun Kim1, Raven D. Hinkel1, Claire Aibel 1 Ismet C. Tanrikulu 1, Christopher B. Rohde1, Matthew Angel1 1Factor Bioscience Inc., Cambridge, MA
Use of pro- (e.g., IL7 and IL15) and anti-inflammatory cytokines (e.g., IL4 and IL10) are being explored in cell therapy for their roles in directing and enhancing immunomodulation and survival of immune cells to alleviate conditions such as cancer and inflammatory disease, respectively. Due to their natural capacity to target inflamed and cancerous tissues, alongside […]
Raven Dance Hinkel1, Elizabeth Belcher1, Christopher B. Rohde2, Matthew Angel2, Kyle M. Garland1
1Eterna Therapeutics Inc., Cambridge, MA, 2Factor Bioscience Inc., Cambridge, MA
Mol Ther, Vol 32, No 4S1, 2024
While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses. This variability is often attributed to donor and source heterogeneity and limited expansion potential. Furthermore, MSCs can exhibit limited in vivo persistence due to clearance by host immune […]
Taeyun Kim1, Raven D. Klee2, Ismet Caglar Tanrikulu1, Christopher B. Rohde1, Matthew Angel1 1Factor Bioscience Inc., Cambridge, MA, 2Eterna Therapeutics Inc., Cambridge, MA
Induced pluripotent stem cells (iPSCs) provide an ideal starting point for the generation of gene-edited tissue-specific cells. In particular, engineered iPSC-derived mesenchymal stromal cells (iMSCs) combine the advantages of tissue-derived MSCs (immunomodulation, clinical safety, low immunogenicity, tissue penetration, etc.) with gene editing (e.g., overexpression or knock-out of immunomodulatory factors), and thus, presents anew pathway for […]
Claire Aibel1, Abigail Blatchford1, Christopher B. Rohde1, Matthew Angel1 1Factor Bioscience Inc., Cambridge, MA
Induced pluripotent stem cell (iPSC)-derived therapies hold potential for increased scalability, broader accessibility, and superior production of genetically identical cells compared to traditional allogeneic approaches. Clonal populations of immune cells expressing therapeutic transgenes can be generated from gene-edited iPSCs. Synthetic promoters are often paired with such transgenes, as they can drive high levels of protein […]
Elizabeth Belcher1, Raven Dance Hinkel1, Christopher B. Rohde2, Matthew Angel2, Kyle M. Garland1
1Factor Bioscience Inc., Cambridge, MA, 2Eterna Therapeutics Inc., Cambridge, MA
Allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) are an exceptionally promising class of cellular therapeutic, as they can greatly reduce the manufacturing complexities of autologous and donor-derived allogeneic cell therapies such as scalability, batch-to-batch consistency, and cost. However, host immune cell recognition and clearance of exogenous cells can lead to iatrogenic toxicities […]
